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The global research trends and potential gaps in global research on thymic epithelial tumours (TETs) were 
scientometrically identified based on the data retrieved from Web of Science (WoS). The analysis indicates that the global 
research on TETs is presenting a positive growth trend. The transformative activity index (TAI) value depicts that three 
Asian countries, China, South Korea, and India, recorded the highest increase in TAI during the last decade, while the 
maximum decline in TAI was for Norway, Taiwan and Netherlands. The University of Texas has published most papers on 
TETs, and Heidelberg University had the highest collaboration. There is not enough research ongoing on some 
paraneoplastic disorders associated with TETs like cerebellar degeneration, erythrocytosis, pancytopenia, rheumatoid 
arthritis, Sjogren’s syndrome, interstitial pneumonitis, chronic mucosal candidiasis, T-cell deficiency syndromes, ulcerative 
colitis, and hypertrophic osteoarthropathy. Most of the TET treatment studies were on surgery and chemotherapy. Research 
on other treatment modalities like immunotherapy and targeted therapy also needs improvement. 
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Introduction 
Thymic epithelial tumours (TET) are comparatively 
rare thoracic neoplasms originating from the thymus 
but are the most common anterior mediastinal tumours 
in adults
1-2
. TETs chiefly include thymomas, thymic 
carcinomas, and neuroendocrine tumours
3
. TETs are 
associated with paraneoplastic syndromes, including 
myasthenia gravis and other immune-mediated 
syndromes, in up to 45% of cases
4
. The incidence rate 
of thymoma reported in population studies has ranged 
from 2.2 to 2.6 per million per year, and that of thymic 
carcinoma is around 0.3-0.6 per million per year. The 
data from SEER (Survival, Epidemiology, and End 
Results) shows that average thymoma incidence rates 
range from 1.3 to 1.5 million per year but are about 
three times higher in Asians and Pacific islanders 
inside USA
3
. The field of thymic tumours suffers from 
a profound lack of prospective studies, and the few 
available clinical trials are with limited numbers of 
patients
5
. As TETs are rare, they are precluded from 





 analysed Scopus indexed articles and 
reviews on oral erythroplakia and leukoplakia up to 
2016 and concluded that only 4% of oral oncology 
research was focused on the selected topic and 




 examined the published research on 
lung cancer by 24 leading countries from 2004 to 
2013 using the WoS database. Apart from China, the 
commitment by most countries to lung cancer 
research has dwindled. Most lung cancer research was 





 studied mesothelioma 
research using scientometrics and noted an 
association between a country’s research commitment 
and disease burden.
 
The research on pancreatic cancer 
is constantly progressing, and significant output was 





USA was in the leading position in both research 
quantity and quality of triple-negative breast cancer 
research, and the number of papers from China is 
rapidly increasing, but the quality of articles still 
requires improvement
11
. Dwivedi et al.
12
 pointed out 
that the global research output on male breast cancer 
is growing. Though the publications from China were 
rapidly increasing, the impact remains less.
  
The United States topped in quantity and quality of 
breast cancer research output, and publications with 
high levels of international cooperation were received 
more citations
13
. Europe was the most productive 
continent in eye neoplasm research, followed by 








The global scientific 
performance on ovarian cancer research is 
concentrated in few countries, including the USA, 
UK, China, Germany, Japan, and Italy. Other Asian, 
South American, and African countries had scant 





90 per cent of publications on myeloma were from the 
USA and European Union, and global multiple 
myeloma research output has increased significantly 




There is no exclusive 
scientometric analysis on thymic epithelial tumours 
(TET) in the literature.  
 
Objective of the study 
 To analyse research trends, geographical 
distribution, collaboration patterns, identifying the 
areas of attention, potential gaps, and examine the 
top-cited papers in global TET research. 
 
Methodology 
Data was collected from the core collection of 
Science Citation Index from Web of Science (WoS) 
in February 2020 using the following search string 
formed by referring to ―WHO Classification of 
Tumors of the Lung Pleura Thymus and Heart ―
3
. 
Query: (((((TOPIC: (carcinoma NEAR (thymus OR 
thymic)) OR TOPIC: (adenocarcinoma NEAR (thymus 
OR thymic))) OR TOPIC: (carcinoid NEAR (thymus 
OR thymic))) OR TOPIC: (lipofibroadenomas)) OR 
TOPIC: (thymoma)) OR TOPIC: ("neuroendocrine 
tumo*" NEAR (thymus OR thymic))) Timespan: 
1945-2019.  
The 8732 papers retrieved from WoS were 
examined manually and selected 6590 publications 
that discussed any of the TETs or diseases associated 
with it that are relevant to humans. Papers that 
discussed TETs in the ectopic positions were 
excluded. These results were analysed by different 
quantitative techniques based on scientometrics using 
Bib-Excel, VOSviewer, and MS Excel.  
 
Results and discussion 
 
Research Growth 
The earliest research paper on TET indexed in 
WoS is the paper titled ‘Malignant thymoma’ 
published in 1945 in the Canadian Medical 
Association Journal. Thereafter, the TET research has 
grown exponentially (Figure 1) in each decade with 
an R
2
 value of 0.98 till 2010. We can see a slight 
decline in the current decade for the exponential 
growth with an R
2 
value of 0.97. The research papers 
were cited throughout the period, with an average 
citation per publication being 20 to 25. In the last five 
years, more than 300 papers were published every 
year on TET research. 
 
Geographical Distribution of TET Research 
The research on TETs is ongoing in more than 88 
countries. Table 1 shows the first ten country’s 
research outputs in different decades and the 
 
 
Fig. 1 — Growth of TET Research 




Transformative Activity Index (TAI). During 1972-
79, only 21 countries published on TETs research, 
and in the next decade (1980-89), it increased to 26 
countries. Then more and more countries were 
involved in research on TETs—45 countries in 1990-
99, 64 countries in 2000-09, and 74 countries during 
2010-2019. The USA published the highest number of 
research papers (1608) and showing steady growth 
over the years, followed by Japan, Italy. Research in 
South Korea, Taiwan, Turkey, and India started after 
1990 and TET research in these countries has grown 
steadily since 2009. 
For analysing the relative change in the output of 
most prolific countries, we used the Transformative 
Activity Index (TAI) of Guan and Ma
17
, which can be 
defined mathematically as:  
TAI = [(Ci /Co )/(Wi /Wo )] x100  
Ci is the number of publications of the specific 
country in the i
th
 block 
Co is the total number of publications of the 
specific country during the period of study 




Wo is the number of publications of all the 
countries during the period of the study 
Table 1 represents the change in the value of TAI 
for most productive countries. The TAI value for 
different countries suggests that TET research growth 
has increased in the USA, Italy, China, France, South 
Korea and India during the last decade. Notably, 
Asian countries like China, South Korea, and India 
show rapid progress in the past decade. The TAI 
value of Japan, Germany, the UK, Spain, Turkey, and 
Canada does not show a positive growth trend. The 
maximum decline in TAI was noted for Norway, 
Taiwan and Netherlands, while the highest hike was 
for China and South Korea. 
 
Prolific institutions in TET research 
Four thousand institutions published papers on 
TET research, but only 435 institutions have 
published more than five papers during the study 
period. The ten most prolific institutions responsible 
for publishing 32% of the total TET research globally 
are listed in Table 2. The first five institutions have 
contributed more than 100 papers and together 
Table 1 — Research output and changes in TAIof prolific countries 
Rank Country Research papers (P) TAI Change in  
TAI 
  1972-2019 1972-1979 1980-1989 1990-1999 2000-2009 2010-2019 2000-2009 2010-2019 
1 USA 1608 70 109 255 391 783 100 102 (+)2 
2 Japan 1075 6 33 163 307 566 118 111 (-)7 
3 Italy 565 4 16 87 149 309 109 115 (+)6 
4 P R China 529 1 2 26 41 459 32 182 (+)150 
5 Germany 382 11 26 77 96 172 103 95 (-)8 
6 UK 331 9 26 60 88 148 109 94 (-)15 
7 France 326 14 30 45 78 159 99 102 (+)3 
8 South Korea 177 0 0 9 40 128 93 152 (+)59 
9 Taiwan 148 0 0 25 60 63 167 89 (-)78 
10 Spain 135 6 5 18 38 68 116 106 (-)10 
11 Turkey 133 0 0 3 48 82 149 129 (-)20 
12 Canada 127 8 11 24 31 53 100 88 (-)12 
13 Netherlands 104 1 7 10 37 49 146 99 (-)47 
14 India 100 0 0 4 27 69 111 145 (+)34 
15 Norway 99 0 7 29 41 22 170 47 (-)123 
 
Table 2 — Citation analysis of top ten institutions 
Rank Institutions Papers (P) Total citations (TC) Citations per paper  (CPP) 
1 University of Texas, USA 184 4337 23.57 
2 Mayo Clinic, USA 121 4590 37.93 
3 Memorial Sloan Kettering Cancer Center, USA 116 3689 31.8 
4 Nagoya City University, Japan 103 2079 20.18 
5 Heidelberg University, Germany 100 2034 20.34 
6 Osaka University, Japan 98 2471 25.21 
7 National Cancer Center, Japan 86 2016 23.44 
8 Indiana University, USA 80 1940 24.25 
9 Sapienza University of Rome, Italy 78 1463 18.76 
10 University of Bergen, Norway 76 3056 40.21 
 




contributed 10% of the entire TET research. Out of 
the top ten most prolific organisations, four institutes 
were from North America (USA), three from Europe 
(Germany, Norway, and Italy), and three from Asia 
(Japan). This data shows that TET research is 
concentrated in a few institutions 
 
Scientific collaboration on TET Research  
The high-quality research output comes from 
collaborative research
18
. International co-authorship 
was mapped and analysed using the VOSviewer. The 
USA collaborates with most countries, and the highest 
collaboration occurred with Italy, resulting in 68 
research papers. The partnership between countries in 
North America and Europe had published most 
papers, followed by countries within Europe. Japan 
and China were in the top ten list, and both had 
published in collaboration with the USA. Among the 
Asian countries, Japan published most with other 
countries. Brazil is the only South American country 
that had collaborative research with North American 
countries. 
Figure 2 shows the multi-institutional 
collaboration; there are seven major clusters of 
collaborations; the bubble’s size is proportional to the 
institute’s research papers. At the same time, the line 
width indicates the collaboration strength. Heidelberg 
University (Germany) had the maximum number of 
collaborations. University of Texas (USA) has 
published most papers, and the University of Bergen 
(Norway) has got the highest number of citations per 
paper among the top ten institutes.  
The only international collaboration amongst the 
top twenty collaborating institutes occurred between 
the University of Turin-Italy, and Yale University-
USA. The researchers in Haukeland University 
Hospital and the University of Bergen, both in 
Norway, have the most number of publications in 
collaboration (25). Memorial Sloan Kettering Cancer 
Center-USA (62) was involved in the highest number 
of partnerships with other institutes.  
 
Prominent journals 
The 6590 research papers were published in 1200 
journals; however, most research is concentrated in a 
few journals. The top ten journals are listed in  
Table 3. The first 25 per cent of the research articles 
were published in the top one percentage (12) 
 
 
Fig. 2 — Institutional collaboration in TET research 




journals. The first 50% of the articles were published  
in 5.5% (58) journals. The ‘Journal of Thoracic 
Oncology’ was the most preferred journal with 496 
(7%) papers; however, many (68%) of the papers 
published in this journal are not cited. The publications 
in the journal ‘Annals of Thoracic Surgery’ have 
received the highest number of citations.  
 
Keyword analysis 
Using text analysis, the author keywords were 
listed and classified based on the treatment, diagnosis, 
disorders associated with TETs, molecular biology & 
immunology, prognosis & survival, and staging 
systems. Keywords with at least three occurrences 
were selected for keyword analysis.  
There were 1474 keywords related to various 
treatment specialities; of that, the most frequent keyword 
was surgery (52%), followed by chemotherapy (22%), 
radiotherapy (11%), immunotherapy (9%), targeted 
therapy (2%) and other therapies (4%).  
Thymectomy was used in 285 papers related to 
surgical treatment, followed by minimally invasive 
surgery (MIS) (129). Video-assisted thoracoscopic 
surgery (58) was the most common keyword in the 
MIS techniques, followed by robotic surgery (33). 
Thymectomy may also be performed using MIS
19
. 
However, only a few papers had discussed 
thymomectomy(17).  
Thymic tumours are responsive to chemotherapy, 
and the chemotherapy in combination with cisplatin 
proved to be most effective
20
. Among the 
chemotherapy drugs discussed, cisplatin was in the 
first position (23), followed by paclitaxel (17) and 
carboplatin (11). Platinum-based chemotherapy has 
been using as the first-line treatment for patients with 
advanced or metastatic TETs
21
. However, the studies 
on platinum-based chemotherapy were only seven. 
Immunosuppressive therapy has been reported to 
be useful for thymoma-associated secondary pure red 
cell aplasia
22
. The most commonly used 
immunosuppressants are cyclosporine A, tacrolimus, 
rapamycin and its synthetic derivative everolimus, 
corticosteroids, azathioprine, and mycophenolate 
mofetil
23
. There were 132 keywords related to 
immunotherapy. Among the immunosuppressants, 
corticosteroids (29) stood first, followed by 
cyclosporine (13), tacrolimus (10), and cyclosporine A 
(9). Radiotherapy was in 161, and targeted therapy was 
discussed in 36 papers. Sunitinib (12) was the widely 
used drug for targeted therapy. Sixty-two publications 
dealt with other treatment approaches, of that only a 
negligible number of studies on proton therapy (3). 
We classified the 1351 keywords related to TET 
associated paraneoplastic disorders with the help of 




Paraneoplastic neuromuscular diseases (900) were 
the most discussed TET associated disorder, followed 
by immune deficiency disorders (132). Among the 
neuromuscular diseases, a substantial part (727) was 
myasthenia gravis (MG), followed by neuromyotonia 
(40) and encephalitis (34). Good syndrome 
(Hypogammaglobulinaemia) was the most discussed 
immune deficiency disorder; however, T-cell 
deficiency syndrome has not received enough attention. 
Among the paraneoplastic haematological 
disorders (94 keywords), a significant portion was on 
pure red cell aplasia (58), followed by aplastic 
anaemia (10). Other TET-associated haematological 
disorders like pancytopenia, erythrocytosis, and 
pernicious anaemia, have not obtained adequate 
consideration. Paraneoplastic endocrine disorders 
were included in 87 papers; Cushing’s syndrome (53) 
was the most discussed endocrine disorder, followed 
by multiple endocrine neoplasias (31). Paraneoplastic 
dermatological disorders were covered only in 24 
papers, and pemphigus (16) was the most studied. 
Table 3 — Prominent journals 








Percentage of Not 
cited Papers 
1 Journal of Thoracic Oncology 13.357 496 3884 7.83 68.35 
2 Annals of Thoracic Surgery 3.639 223 6832 30.64 9.42 
3 European Journal of Cardio-Thoracic Surgery 3.486 123 2051 16.67 14.63 
4 Journal of Thoracic Disease 2.046 119 357 3.00 35.29 
5 Cancer 5.742 117 6597 56.38 1.71 
6 Journal of Thoracic and Cardiovascular Surgery 4.451 90 3408 37.86 12.22 
7 Lung Cancer 4.702 81 1351 16.68 13.58 
8 Journal of Clinical Oncology 32.956 78 2214 28.38 35.90 
9 Chest 8.308 78 1386 17.77 37.18 
10 Laboratory Investigation 4.197 76 161 2.12 86.84 
 




Another paraneoplastic dermatological disorder, 
chronic mucosal candidiasis, has not received 
sufficient attention. The systemic lupus erythematosus 
(19) and scleroderma (4), which are collagen and 
autoimmune disorders, were discussed only in a few 
studies. The rest of the diseases classified under 
miscellaneous paraneoplastic syndromes, nephrotic 
syndrome (24), and superior vena cava syndrome (19) 
were the most discussed.  
A few studies reported a higher risk of cancer for 
thymoma patients
25-26
. Lymphomas (50) were the 
most discussed neoplasm that was discussed in TET 
papers, followed by lung cancer (38) and leukaemia 
(10). Breast cancer and prostate cancer were 
discussed in five, and oesophagal cancer was included 
in three papers. Other cancers were discussed only in 
very few publications. 
Areas in immunology and molecular biology were 
discussed in 321 papers. Among that, 61 were on 
autoantibodies, followed by T cells (27). Prognosis of 
the disease was involved in 182 papers, survival in 76, 
and the disease’s recurrence was discussed in 68 
studies. There are around 15 stage classification 
systems for thymic tumours; the Masaoka-Koga 




TETs for the first time were included in the TNM 
staging system because of the joint effort of the 
International Thymic Malignancy Interest Group 
(ITMIG), the International Association for the Study 
of Lung Cancer (IASLC), and the contribution of 
several important databases
29-30
. The classification and 
staging systems of TETs were discussed in 111 
papers. Masaoka staging system (40%) was the  
most used, followed by WHO classification (29%). 
Though TNM classification for TETs has started 
recently, it was the third most discussed classification 
system (13%); this indicates that TNM classification 
will be the most important system in the future for 
staging TETs. 
Keywords are also classified based on their use in 
the diagnosis of TETs. Diagnosis is again classified 
into pathology (35%), medical imaging tests (29%), 
biomarkers (12%), and other diagnostic techniques 
(25%). There were 253 papers related to pathology; 
64% (161) of those were related to 
immunohistochemistry. Titin antibodies are using to 
detect thymoma in MG patients and may serve as 
biomarkers to monitor therapeutic responses
31
. 
Eighty-four papers discussed biomarkers; titin 
antibodies (23) was the most discussed biomarker, 
followed by C-KIT (12). Diagnostic imaging was 
discussed in 204 studies. Computed tomography (CT) 
was the most used imaging test (46%), followed by 
positron emission tomography (PET) (24%), magnetic 
resonance imaging (12%), and PET-CT (8%). 
Positron emission tomography (PET) scan using 
fluorine18 fluorodeoxyglucose (FDG) is a powerful 
tool for diagnosing, staging and restaging several 
malignancies, including TETs
32-33
. By analysing 
keywords, it can be found that PET is also emerging 
as one of the critical tools involved in the studies on 
TETs. Amongst the 180 keywords about the other 
diagnostic techniques, the anti-acetylcholine receptor 
antibody was included in 80 papers, followed by 
thoracoscopy (23).  
We examined the title and abstract of papers 
regarding the average publication year to understand 
the active research topics. The topics with an  
average publication year greater than 2014 were 
considered as TET active research areas. The 
important topics were anthracycline, gemcitabine, 
capecitabine, temozolomide, pembrolizumab, 
Masaoka-koga staging, intensity-modulated radiation 
therapy, proton therapy, receiver operating 
characteristic curve, the area under the curve, 
programmed cell death-ligand-1, international thymic 
malignancy interest group, and the myasthenia gravis 
foundation of America.  
The topics on which research has tapered off  
are analysed from words with an average publication 
year less than 2001. This list includes erythro-
blastopenia, pancytopenia, giant cell myocarditis, 
chronic mucocutaneous candidiasis, lymphocytosis, 
agranulocytosis, peripheral neuropathy, polymyositis, 
and Muller hermelink classification. Paraneoplastic 
disorders included in this list, such as pancytopenia, 
giant cell myocarditis, and polymyositis, are included 
in the list of autoimmune disorders in ESMO clinical 
practice guidelines for TETs 2015
24
. 
The overlay visualisation of the title word analysis is 
given in Figure 3. From the analysis, it can be seen  
that the research focus, in the beginning, was  
malignant thymoma and MG, then thymic carcinoids. 
Some of the paraneoplastic disorders like myocarditis, 
paraneoplastic autoimmune hematologic, and 
endocrine disorders were the later leading TET 
research areas. Afterwards, antibodies, including  
titin antibodies, acetylcholine receptor antibodies,  
and autoantibodies, have received sufficient attention 




from researchers. Then the thymic carcinoma, 
neuroendocrine tumours, biopsies, staging, 
classification of tumours, and treatment methods like 
radiotherapy and chemotherapy (cisplatin, doxorubicin, 
and cyclophosphamide) had gained adequate attention. 
Subsequently, NUT carcinoma, immunotherapy, 
epidemiology, and imaging techniques like computed 
tomography (CT) and magnetic resonance imaging 
were active research areas. In recent years, 
programmed cell death-ligand-1, MIS, PET (including 
FDG PET), and medicines involving amrubicin, 
capecitabine (chemotherapeutic drugs), and sunitinib, 
that is used for targeted cancer therapy were the latest 
core areas of TET research. Notably, most 
paraneoplastic disorders are not the current vital areas 
of research. The title text analysis also reveals that the 
study on paraneoplastic disorders associated with 
TET shows negative growth. 
 
Most cited papers 
The Review paper on ‘Myasthenia gravis - 
recommendations for clinical research standards’
34
 
published by a group of authors from Myasthenia 
Gravis Foundation of America in 2000 in the  
journal Neurology has been cited 702 times  
(citation data: May 5, 2020). The top three  
highly cited papers
34-36 
that have been cited more  
than six hundred times are related to the 
paraneoplastic syndromes associated with TETs.  
The first and third most cited publications are  
review papers.  
 
Top cited papers published within the last five years 
Table 4 lists the highly cited papers published  
in the past five years. As in the top-cited paper  
list, the most cited paper (240 citations) within  
the last five years is also on MG. Unlike the  
titles in the list of highly cited papers, it can be 
observed that some topics like eculizumab 
(immunotherapy drug), sunitinib (used for targeted 
therapy), and programmed cell death-ligand 1 (used 
for immunotherapy and as a marker for tumour 
prognosis) have emerged in the titles of the recent 




Fig. 3 — Text analysis: Overlay visualisation 
 





Based on the available epidemiologic data, Asians 
and Pacific islanders have a higher rate of thymoma
3
. 
The transformative activity index data suggests that 
the research on TET is rapidly increasing in some 
Asian countries, including China, South Korea, and 
India. TET treatment requires a multidisciplinary 
approach as the multidisciplinary treatment approach 
has proved to be more effective for TETs
37
. However, 
74% of the studies on TET treatment were on surgery 
and chemotherapy; hence the research on other 
treatment modalities like immunotherapy, targeted 
therapy needs to be improved. Anthracycline, 
amrubicin, gemcitabine, capecitabine, temozolomide, 
sunitinib, and pembrolizumab were the most 
discussed medicines by TET for better patient care 
and management. 
Nearly 25 to 40% of thymoma patients have MG, 
and 15% of thymoma patients having paraneoplastic 
diseases other than MG
38-39
. It is observed from  
this study that there is not enough research ongoing 
on some paraneoplastic disorders associated with 
TETs like cerebellar degeneration, erythrocytosis, 
pancytopenia, rheumatoid arthritis, Sjogren’s 
syndrome, interstitial pneumonitis, chronic mucosal 
candidiasis, T-cell deficiency syndromes, ulcerative 
colitis, and hypertrophic osteoarthropathy. The 
research on erythroblastopenia, giant cell myocarditis, 
lymphocytosis, agranulocytosis, peripheral neuropathy, 
and polymyositis decreases over the past years. This 
study points out that the global research on TET is 
steadily increasing, though the researchers need to 
focus more on the rare paraneoplastic disorders 
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